Crossmark

Distinct clinical and prognostic implication of IDH1/2 mutation and other most frequent mutations in large duct and small duct subtypes of intrahepatic cholangiocarcinoma

Crossref DOI link: https://doi.org/10.1186/s12885-020-06804-6

Published Online: 2020-04-15

Published Print: 2020-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ma, Bingqi

Meng, Huijuan

Tian, Ye

Wang, Yingying

Song, Tianqiang

Zhang, Ti

Wu, Qiang

Cui, Yunlong

Li, Huikai

Zhang, Wei

Li, Qiang
Funding

Funding for this research was provided by:

National Natural Fund Project (81572434)

Ministry of Science and Technology, National Science and Technology Major Special Project: Prevention and Treatment of Major Infectious Diseases such as AIDS and Viral Hepatitis (2018ZX10723204-007-001)

Young Medical Elites (Tianjin Health Commission, 2018.12-2020.1)

Young Innovative Talents (Tianjin Medical University Cancer Institute and Hospital, 2017.1-2019.12)
License Information

Text and Data Mining valid from 2020-04-15

Version of Record valid from 2020-04-15
More Information

Article History

Received: 2 February 2020

Accepted: 29 March 2020

First Online: 15 April 2020

Ethics approval and consent to participate

: The Medical Ethics Committee of Tianjin Medical University Cancer Institute and Hospital approved this study (Approval No.: bc2019065). Informed consents were obtained from all patients or their legal guardian.

: The typical ICC patient with IDH1 mutation provided informed written consent to the use of clinical data and MR images for publication.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below